

Matriptase (h): 293T Lysate: sc-170663

BACKGROUND

Matriptase (also known as MT-SP1, ST14, prostamin and epithin) is a tumor-associated type II transmembrane serine protease that is highly expressed in many human cancer-derived cell lines and is implicated in extracellular matrix remodeling, tumor growth and metastasis. Matriptase performs pleiotropic functions in the development of the epidermis, hair follicles and cellular immune system. Sphingosine 1-phosphate (S1P, SPP), present in serum-derived lipoproteins, activates Matriptase, while Matriptase activates both urokinase-type plasminogen activator and hepatocyte growth factor (HGF). Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is a Kunitz-type serine protease inhibitor identified as a strong inhibitor of Matriptase and HGF. Advanced-stage ovarian tumors that express Matriptase are more likely to do so in the absence of its inhibitor, HAI-1, indicating that an imbalance in the Matriptase: HAI-1 ratio could be important in the development of advanced disease.

REFERENCES

1. Cho, E.G., Kim, M.G., Kim, C., Kim, S.R., Seong, I.S., Chung, C., Schwartz, R.H. and Park, D. 2001. N-terminal processing is essential for release of epithin, a mouse type II membrane serine protease. *J. Biol. Chem.* 276: 44581-44589.
2. Friedrich, R., Fuentes-Prior, P., Ong, E., Coombs, G., Hunter, M., Oehler, R., Pierson, D., Gonzalez, R., Huber, R., Bode, W. and Madison, E.L. 2002. Catalytic domain structures of MTSP1/Matriptase, a matrix-degrading transmembrane serine proteinase. *J. Biol. Chem.* 277: 2160-2168.
3. Oberst, M.D., Johnson, M.D., Dickson, R.B., Lin, C.Y., Singh, B., Stewart, M., Williams, A., al-Nafussi, A., Smyth, J.F., Gabra, H. and Sellar, G.C. 2002. Expression of the serine protease Matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. *Clin. Cancer Res.* 8: 1101-1107.
4. List, K., Haudenschild, C.C., Szabo, R., Chen, W., Wahl, S.M., Swaim, W., Engelholm, L.H., Behrendt, N. and Bugge, T.H. 2002. Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. *Oncogene* 21: 3765-3779.
5. Benaud, C., Oberst, M., Hobson, J.P., Spiegel, S., Dickson, R.B. and Lin, C.Y. 2002. Sphingosine 1-phosphate, present in serum-derived lipoproteins, activates Matriptase. *J. Biol. Chem.* 277: 10539-10546.
6. Denda, K., Shimomura, T., Kawaguchi, T., Miyazawa, K. and Kitamura, N. 2002. Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 1. *J. Biol. Chem.* 277: 14053-14059.
7. Ihara, S., Miyoshi, E., Ko, J.H., Murata, K., Nakahara, S., Honke, K., Dickson, R.B., Lin, C.Y. and Taniguchi, N. 2002. Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active Matriptase by adding β 1-6 GlcNAc branching. *J. Biol. Chem.* 277: 16960-16967.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

CHROMOSOMAL LOCATION

Genetic locus: ST14 (human) mapping to 11q24.3.

PRODUCT

Matriptase (h): 293T Lysate represents a lysate of human Matriptase transfected 293T cells and is provided as 100 μ g protein in 200 μ l SDS-PAGE buffer.

APPLICATIONS

Matriptase (h): 293T Lysate is suitable as a Western Blotting positive control for human reactive Matriptase antibodies. Recommended use: 10-20 μ l per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.